These studies indicate that the major reservoir of OCP in PsA is CD16+ cells, a finding that may catalyze the development of susceptibility biomarkers for arthritis in Ps patients and a treatment response marker in PsA patients with erosive arthritis. This evidence concerns the gene FCGR3A and Arthritis.